Infliximab (IFX) is the in vitro synthesis of TNF-α human-mouse chimeric monoclonal antibodies, can be combined with TNF-α and blocking its biological activity.[16] IFX respectively in 1998 grade 1999 approved by the FDA and the EMA, used in the treatment of the AS, rheumatoid arthritis, psoriasis, and crohn’s disease and the treatment of the disease such as ulcerative colitis. This evidence concerns the gene TNF and psoriasis.